by myTomorrows | 12 Dec 2019
myTomorrows and Inmunotek to develop Expanded Access Program
Amsterdam, The Netherlands and Madrid, Spain, 12 December, 2019– myTomorrows, a Netherlands-based HealthTech company facilitating access to medicines in development and real-world data collection, and Inmunotek – with headquarters in Madrid, Spain – a global player in allergy and immunity-based bacterial vaccines, today announced a collaboration to develop an Expanded Access Program (EAP) for the unlicensed bacterial vaccine Uromune.
Inmunotek is progressing Uromune in a clinical development program as a vaccine for patients with recurrent Urinary Tract Infections (rUTIs). The Expanded Access Program will support the supply of Uromune, when prescribed on a Named Patient basis.
Steve Glass, COO of myTomorrows said, “I am delighted that myTomorrows has found a partner in Inmunotek. With our unique online platform, combined with our global capabilities of supporting expanded access we aim to accelerate access to a medicine in development and serve patients with an unmet medical need.”
Prof. Jose Luis Subiza, MD, CEO of Inmunotek commented, “This collaboration with myTomorrows will allow Inmunotek to expand its geographical presence, to the benefit of those patients who have no other treatment options available. Also, this collaboration will likely contribute to a better understanding of the unmet needs of patients suffering rUTI’s and support further development for concomitant diseases.”
About Expanded Access Programs
An Expanded Access Program (EAP), also known as Managed Access Program, supports in a compliant and controlled way the treatment with a medicine currently not licensed in a patient’s country of residence. Such treatment can be an option for patients who have a high unmet medical need, have exhausted all registered treatment options and cannot participate in a clinical trial.
myTomorrows operates as a two-sided platform. It serves the interests of both patients and healthcare professionals, as well as drug development. On one side, the company provides information on all treatment options to patients and physicians when registered treatments have been exhausted. On the other side, myTomorrows is specialized in expanded access regulations and administration and real-world data collection, evolving scientific clinical development. myTomorrows has gained experience in running over 25 EAPs over the past 5 years, in more than 40 countries across 5 continents. For more information, please visit www.mytomorrows.com.
For enquiries about myTomorrows or expanded access, please contact our medical team via email@example.com.
Inmunotek is a pharmaceutical company based in Alcalá de Henares – Madrid (Spain) that researches, develops, manufactures and markets products in the field of Allergy and Immunology for the diagnosis and treatment of allergic and other immune-based diseases in human and veterinary medicine. For more information about Inmunotek, please visit www.inmunotek.com.
For Inmunotek, please contact:
Dr Miguel Casanovas, Medical Director
T: +34 912 908 942
For myTomorrows, please contact:
Dr. Michel van Harten, CMO
T: +31 88 5253 888